🚀 Exciting news! Concord Biotech, with the backing of Rakesh Jhunjhunwala’s firm, is targeting an IPO launch in August with a potential valuation of up to $1 billion. 🌟 We’re thrilled to be a part of this journey and can’t wait to see what the future holds for this innovative biotech company.
Concord Biotech, a leading biotechnology firm based in Ahmedabad, is preparing to launch its initial public offering (IPO) in early August. The company is backed by Rare Enterprises, the firm of the late veteran investor Rakesh Jhunjhunwala, and healthcare-focused Asian private equity firm Quadria Capital. The updated draft red herring prospectus (UDRHP) was filed with […]
Read More